Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

NSE (neuron specific enolase)

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Neuronal damage
Use
Susceptibility/risk
Predictive
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Despite considerable variability between studies, meta-analysis indicates a significant elevation of neuron specific enolase in the cerebrospinal fluid of people with Alzheimer’s disease (effect size = 1.470, p = 0.01358). This correlation did not hold when analyzing NSE in plasma and serum. Levels of neuron specific enolase do not differ in the plasma and serum between people with Alzheimer’s disease and controls (effect size = 0.999, p = 0.99192).

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Data collected by multiple groups. Alzforum meta analysis.

  1. “Alzheimer's Disease vs Control: NSE (CSF).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-nse-csf

  2. “Alzheimer's Disease vs Control: NSE (Plasma and Serum).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-nse-plasma-and-serum

  3. Schmidt, F. M., Mergl, R., Stach, B., Jahn, I., Gertz, H. J., & Schönknecht, P. (2014). Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease. Neuroscience Letters, 570, 81-85. https://www.ncbi.nlm.nih.gov/pubmed/24746933